Underactivity of A/-methyl-D-aspartate (NMDA) receptor-mediated neurotransmission may play a critical role in schizophrenia (SZ) and, in particular, may underlie persistent negative symptoms and cognitive dysfunction. NMDA receptors are regulated in vivo by the amino acids glycine and D-serine, which bind to a modulatory site on the NMDA receptor complex. Studies using full agonists (glycine and D~serine) and a partial agonist (D-cycloserine) of the NMDA receptor added to conventional or atypical antipsychotics have yielded encouraging, but mixed, results due in part to limitations in the pharamacokinetic/pharmacodynamic properties of the compounds themselves. An alternative approach to raising brain glycine levels is administering compounds that block synaptic glycine reuptake in brain via glycine (GLYT1) transporters. GLYT1 transporters are co-localized with NMDA receptors in the brain and function to limit glycine levels in the immediate vicinity of NMDA receptors. Glycine transport inhibitors have proven effective in numerous animal models of SZ. Although high-affinity glycine transport inhibitors have been developed by several pharmaceutical companies, clinical data are, as yet, unavailable. Sarcosine (A/-methylglycine) is a naturally occurring glycine type I (GLYT1) transport inhibitor that has been reported to improve negative symptoms and cognition in both chronic and acutely decompensated patients in studies conducted in Taiwan, but remains unavailable in the US. In this project, we will perform a randomized, placebo-controlled study of sarcosine as add-on treatment to anti-psychotics in first episode schizophrenia patients in Israel. Use of sarcosine has been approved in Israel based upon the successful clinical trials that were conducted in Taiwan. Studies in Israel will be conducted in accordance with FDA GCP and GLP guidelines and will be supported by Data Management/Biostatistic core (Core C). Neurophysiological outcome measures will be incorporated into the study and will be supported by the Patient Assessment/Recruitment core (Core B). The study will also take advantage of the Israeli Draft Board Registry, which provides objective premorbid data on participating subjects. It is hypothesized that impaired premorbid function will predict more severe neurocognitive and neurophysiological deficit, and greater benefit from an NMDA-based approach.

Public Health Relevance

Schizophrenia is a major mental disorder. Neurocognitive dysfunction is a core component of schizophrenia and a major determinant of poor long-term outcome. This project is part of a Center application to determine brain mechanisms underlying neurocognitive dysfunction in schizophrenia with particular emphasis on sensory processing dysfunction. This project will evaluate the effects of the glycine transport inhibitor sarcosine on persistent neurocognitive deficits in schizophrenia. If successful, it will support a new treatment approach for schizophrenia.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Specialized Center (P50)
Project #
5P50MH086385-04
Application #
8380058
Study Section
Special Emphasis Panel (ZMH1-ERB-F)
Project Start
Project End
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
4
Fiscal Year
2012
Total Cost
$138,515
Indirect Cost
Name
Columbia University (N.Y.)
Department
Type
DUNS #
621889815
City
New York
State
NY
Country
United States
Zip Code
10032
Kantrowitz, Joshua T; Nolan, Karen A; Epstein, Michael L et al. (2017) Neurophysiological Effects of Bitopertin in Schizophrenia. J Clin Psychopharmacol 37:447-451
Lee, M; Sehatpour, P; Hoptman, M J et al. (2017) Neural mechanisms of mismatch negativity dysfunction in schizophrenia. Mol Psychiatry 22:1585-1593
Sershen, Henry; Hashim, Audrey; Dunlop, David S et al. (2016) Modulating NMDA Receptor Function with D-Amino Acid Oxidase Inhibitors: Understanding Functional Activity in PCP-Treated Mouse Model. Neurochem Res 41:398-408
Smiley, John F; Hackett, Troy A; Bleiwas, Cynthia et al. (2016) Reduced GABA neuron density in auditory cerebral cortex of subjects with major depressive disorder. J Chem Neuroanat 76:108-121
Kantrowitz, Joshua T; Epstein, Michael L; Beggel, Odeta et al. (2016) Neurophysiological mechanisms of cortical plasticity impairments in schizophrenia and modulation by the NMDA receptor agonist D-serine. Brain 139:3281-3295
Hillyard, Steven A; Störmer, Viola S; Feng, Wenfeng et al. (2016) Cross-modal orienting of visual attention. Neuropsychologia 83:170-178
van Atteveldt, Nienke; Musacchia, Gabriella; Zion-Golumbic, Elana et al. (2015) Complementary fMRI and EEG evidence for more efficient neural processing of rhythmic vs. unpredictably timed sounds. Front Psychol 6:1663
Javitt, Daniel C (2015) Current and emergent treatments for symptoms and neurocognitive impairment in schizophrenia. Curr Treat Options Psychiatry 1:107-120
Javitt, Daniel C (2015) Neurophysiological models for new treatment development in schizophrenia: early sensory approaches. Ann N Y Acad Sci 1344:92-104
Haegens, Saskia; Barczak, Annamaria; Musacchia, Gabriella et al. (2015) Laminar Profile and Physiology of the ? Rhythm in Primary Visual, Auditory, and Somatosensory Regions of Neocortex. J Neurosci 35:14341-52

Showing the most recent 10 out of 84 publications